Invest in Psychedelics, the Most Underrated Investment Megatrend of the 2020s

Advertisement

Today is a bittersweet day.

It’s bitter because today is the last day of our 1 to 30 Hypergrowth campaign. Three weeks ago, Wall Street icon Louis Navellier and I set out to change your financial future by launching a portfolio of seven hypergrowth technology stocks with 30X upside potential. A week later, I launched an eighth pick. A week after that, I launched our ninth pick. Today, though, we’re closing the book on this amazing opportunity, so your window to access nine different stocks with 30X upside potential is closing.

But it’s sweet because we’re going out with a bang. In celebration of your final opportunity to plug into the 1 to 30 Hypergrowth phenomenon, we’re unveiling a final 10th stock pick with 30X upside potential after the market closes today. Trust me when I say this could be our best pick yet.

Source: InvestorPlace

Let me tell you a little bit about this amazing opportunity…

The Life-Saving Potential of Psychedelics

To start, folks, I’d like to tell you about an absolutely remarkable man by the name of Jonathan M. Lubecky.

He honorably served in both the Marine Corps and the Army from 1995 to 2009. While serving, Lubecky was deployed to active combat zones in Iraq. In the midst of the Iraq War, Lubecky’s Balad base was hit approximately 6,000 times with mortars, bombs, and rockets.

It was intense – so intense that when Lubecky returned to America, he struggled with post-traumatic stress disorder (PTSD), as so many of our noble veterans unfortunately do…

His PTSD was particularly bad. Lubecky fought off suicidal thoughts for a long time. But those thoughts wouldn’t go away, and so one day, Lubecky put a Beretta 9MM gun to his head and pulled the trigger.

But the gun malfunctioned, and Lubecky took that as a sign he was meant to live – to keep fighting his PTSD, and eventually, win. But, despite this sign, he was missing the tools to help him do that.

Until he started reading about MDMA on the internet, and its unique ability to be a “cure” for PTSD in some folks.

He was intrigued. And soon after, Lubecky found himself at the Multidisciplinary Association for Psychedelic Studies (or MAPS, for short) research center in Santa Cruz, California.

There, he met with professionals and was put on an MDMA-inspired therapy routine for his PTSD.

It worked wonders.

Lubecky found that the mind-altering characteristics of MDMA calmed his PTSD in ways that traditional medicine had not, and enabled him to feel embraced in ways he had not felt since before the Iraq War.

It saved Lubecky’s life.

The Return of Psychedelics in the Public Consciousness

As it turns out, Lubecky isn’t the only one whose life has been saved by MDMA, or LSD, or ketamine, or “magic mushrooms.”

All of those drugs belong in a class of drugs we call “psychedelics,” and traditionally, they’ve been frowned upon by society… but things weren’t always like that…

Let’s rewind 70 years.

Back in the 1950s, a group of pioneering psychiatrists in California led by Humphry Osmond were actively experimenting with psychedelics and found that these hallucinogenic drugs had immense therapeutic potential.

More than that, society was falling in love with psychedelics, too. Hollywood’s Cary Grant (star of such classics as North by Northwest) swore by his LSD treatments, of which he had undergone roughly sixty by 1959. After claiming LSD was responsible for his happiness, public interest in the psychedelic surged, leading to patients across the U.S. asking their local psychiatrists for the miracle drug Cary Grant swore by.

But, by the sixties, psychedelics became associated with “hippie” counterculture. And several high-profile “freak outs” (or bad experiences while on a psychedelic) stoked fear of LSD and other psychedelics. What followed was a sociopolitical backlash against “hippie culture” in the 1960s, which included a backlash against psychedelics. Scientists halted their research, and in 1970, psychedelics landed on Nixon’s Schedule 1 drug list.

The book was closed on psychedelic research.

That is, until scientists began questioning the effectiveness of existing treatments and explored new ways of treating mental health disorders such as depression and addiction. They effectively reopened the book on psychedelic research. This new interest blossomed in the late 1990s, found some footing in the early aughts, and then, in the 2010s, psychedelic research absolutely exploded.

A pair of recent Johns Hopkins studies have found that the active ingredient in “magic mushrooms” (something called psilocybin) can significantly help with smoking cessation and reducing alcohol dependence.

An even more recent Johns Hopkins study published in 2020 found that psilocybin can relieve anxiety and depression levels in people with life-threatening cancer diagnoses four times better than traditional antidepressants on the market.

That finding corroborates a previous NYU study, which found that psilocybin causes a “rapid and sustained” reduction in anxiety and depression levels in cancer patients.

Meanwhile, a recent UC Davis study found that psychedelic micro-dosing can produce beneficial behavioral effects in patient with mental health disorders.

An Imperial College London study published in just months ago found that psilocybin is better and faster at treating depression than Lexapro, a leading antidepressant treatment today.

And, most recently, a Yale study published in mid-August 2021 found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.

The list of academic studies goes on and on.

And they are all coming to the same conclusion: psychedelic-inspired medicines have robust therapeutic potential.

Now, with the academic research coming to an indisputable conclusion and mental health awareness on the rise, the legal landscape is starting to peel back antiquated laws that were put in place 50 years ago…

Oregon and Washington D.C. have decriminalized possession of psychedelics. California is set to do the same next year. Canada is on the cusp of doing the same. Same with Michigan and Vermont. The governor of Connecticut just signed legislation to carry out a study into the therapeutic potential of psilocybin mushrooms. The Seattle City Council asked the Overdose Emergency and Innovative Recovery Task Force to explore creating more open policies on psychedelics.

Folks… the sands are shifting. The “Shroom Boom” is coming.

This is great news for the world, because it means that Lubecky’s life won’t be the only one saved from PTSD, or depression, or anxiety, or addiction. Tens of thousands of lives will be saved every single year because of the legalization of psychedelic-inspired medicines.

But this is also great news for you as a hypergrowth investor.

Because in creating a superior treatment for mental health disorders, the Shroom Boom will give birth to a multi-hundred-billion-dollar industry – and you can get in on the ground-floor of this investment megatrend by buying the right stocks today.

But, alas, here’s the million-dollar question: What are the best psychedelic stocks to buy today?

There are a handful of great picks in this space. But there is one best stock, with unique 30X upside potential.

And that’s the stock we are going to unveil this afternoon in our 1 to 30 Hypergrowth portfolio.

Don’t miss out. Click here to find out more.


Article printed from InvestorPlace Media, https://investorplace.com/hypergrowthinvesting/2021/09/invest-in-psychedelics-the-most-underrated-investment-megatrend-of-the-2020s/.

©2024 InvestorPlace Media, LLC